Daiichi Sankyo looks outside Japan for growth
This article was originally published in Scrip
Executive Summary
Daiichi Sankyois expecting to complete its acquisition of Ranbaxyby the end of the year, in a move which will further the Japanese company's ambitions of becoming a self-described "global pharma innovator", says president and CEO Takashi Shoda.